<DOC>
	<DOCNO>NCT01257373</DOCNO>
	<brief_summary>The goal study assess long-term efficacy safety Firebird2 Cobalt-Chromium（CoCr）-alloyed sirolimus-eluting stent treatment complex lesion diabetes .</brief_summary>
	<brief_title>Efficacy Safety Firebird 2 Stent Treatment Complex Coronary Lesions Diabetes</brief_title>
	<detailed_description>This clinical trial international multi-center prospective clinical registry research , evaluate efficacy safety Firebird 2 cobalt-chromium alloy sirolimus-eluting stent treatment complex coronary lesion diabetes . As plan , 57 research center China , Latin America Asia-Pacific area involve , 1300 patient enrol research . The implanted stent must Firebird2 cobalt-chromium alloyed sirolimus-eluting stent . The patient enrollment last 12 month . Clinical follow-up do respectively 30 day , 6 month , 12 month , 18 month , 24 month , 30 month 36 month . All quit patient study replace substitute , categorize enrollment failure column . The researcher must state clear reason nonenrollment .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Chromium</mesh_term>
	<mesh_term>Cobalt</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<criteria>Definitely diagnose type 2 DM either current hospitalization complex coronary lesion The coronary lesion comply definition complex type . ( defined protocol ) The investigator admit patient suitable implant Firebird2 CoCralloyed Sirolimuseluting stent ( SES ) Patient his/ legal supervisor provide informed consent . Women pregnancy breastfeeding ; STsegment elevate MI occur within 1 week ; Graft lesion coronary artery bypass graft ( CABG ) operation ; Patient brand stent implant ; LVEF ≤ 35 % ; Renal insufficiency operation ( Serum creatinine ≥ 177umol/L ) Impaired fast glucose（6.0mmol/L～7.0mmol/L）or impair glucose tolerance（OGTT 2h blood glucose 7.8mmol/L～11.1mmol/L）patient ; Recent PCI within 6 month previous intravascular radiotherapy ; Predicted life span le 12 month ; Patient allergic follow material : aspirin , heparin , Clopidogrel , CoCr alloy , contrast agent sirolimus . Recent participation trial medication device study without endpoint completion clinically interfere FIRE2－DIABETES study endpoint . Considered investigator unsuitable implant Firebird2 CoCralloyed SES Patients could obey study rule , understand study manner , scope outcome , cooperative , provide informed consent , accept followup , finish whole study procedure .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2009</verification_date>
</DOC>